Live Breaking News & Updates on பாடதி இமாச்சல் பிரதேஷ்

Stay informed with the latest breaking news from பாடதி இமாச்சல் பிரதேஷ் on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in பாடதி இமாச்சல் பிரதேஷ் and stay connected to the pulse of your community

Lifecare Neuro Products Ltd receives Neuro-Psychiatric Company of the Year 2021 Award

Lifecare Neuro Products Ltd receives Neuro-Psychiatric Company of the Year 2021 Award
aninews.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from aninews.in Daily Mail and Mail on Sunday newspapers.

India , Himachal-pradesh , Sun-pharma , Baddi-himachal-pradesh , Yogendra-chopra , Third-party-manufacturing , Psychiatric-company-of-the-year , Quality-innovative-solutions , Lifecare-neuro-products-ltd-india , Biocon , Lifecare-neuro-products-ltd , Heylin-spark

Panacea Biotec surges 9% on DCGI's nod to produce Sputnik V vaccine

Shares of Panacea Biotec surged 9 per cent to Rs 411 on the BSE in the intra-day trade on Monday after the company announced that it has received a manufacturing license to produce Sputnik V vaccine at its Baddi (Himachal Pradesh) plant. The stock of one of the leading vaccine and pharmaceutical producers in India had hit a 52-week high of Rs 453.70 on May 28, 2021.
"The company announces receipt of manufacturing license from Drugs Controller General (India) for Sputnik V vaccine against Covid-19 pursuant to its collaboration with Russian Direct Investment Fund (Russia's sovereign wealth fund). The license is a necessary condition for using Sputnik V produced by Panacea Biotec in India," Panacea Biotec said in a press release on Sunday, July 4, 2021.

India , Russia , Russian , Baddi-himachal-pradesh , Russian-direct-investment-fund-russia , Panacea-biotec , Himachal-pradesh , Drugs-controller-general , Russian-direct-investment-fund , இந்தியா , ரஷ்யா , ரஷ்ய

Venus Remedies wins legal battle against French firm for paracetamol patent

Venus Remedies wins legal battle against French firm for paracetamol patent
indiatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiatimes.com Daily Mail and Mail on Sunday newspapers.

Delhi , India , France , French , Saransh-chaudhary , Baddi-himachal-pradesh , Indian-patent-office , Delhi-high-court , Venus-remedies , Remedies-president , Global-critical-care , Intellectual-property-appellate-board

Sputnik V vaccine: Panacea Biotec, RDIF begin production - The Hindu BusinessLine

Panacea will manufacture 100 million doses of the Russian vaccine per year

Delhi , India , Russia , Lalru , Punjab , Russian , Baddi-himachal-pradesh , Kirill-dmitriev , Rajesh-jain , Stelis-biopharma , Virchow-biotech-private , Gamaleya-center-the-moscow

Tax evasion: Ludhiana customs seizes 14 containers | Ludhiana News

In crackdown against tax evasion, the customs commissionerate Ludhiana has seized 14 containers in four different cases of misdeclaration involving du

Ludhiana , Punjab , India , Mandi-gobindgarh , Baddi-himachal-pradesh , Arvinder-singh-ranga , Customs-act , Ludhiana-news , Udhiana-latest-news , Udhiana-news-live , Udhiana-news-today

125% jump in a month, 360% in a year; safety rush turns this laggard a multibagger

Explore Now
NEW DELHI: As India faces the worst wrath of a deadly second wave of the Covid-19 pandemic and markets turn volatile due to various localized curbs and restrictions, investors are rushing towards safe heavens like pharma, FMCG and IT stocks to avoid wealth erosion.
Pharma smallcap
Morepen Laboratories has been thumping rock and roll over the past few weeks; it delivered multibagger returns for last financial year, and has already delivered over 125 per cent return for this financial year so far, up from Rs 32 on April 1. It has so far risen 365 per cent from its 52-week low hit on May 22 last year. The stock has also hit a 19-year high in the process.

Australia , India , Switzerland , Baddi-himachal-pradesh , Gaurav-garg , Investment-strategist-at-geojit-financial-services , Head-of-research-at-capitalvia-global , Corinth-investment-holdings , Chief-investment-strategist , Geojit-financial , Securities-appellate-tribunal , Capitalvia-global-research

Covid-19 vaccine: Panacea Biotec to begin Sputnik V manufacturing within 90 days

Covid-19 vaccine: Panacea Biotec to begin Sputnik V manufacturing within 90 days
April 10, 2021
Sputnik V at Panacea Biotec sites will be supplied to the international partners of RDIF. - REUTERS
Sputnik V at Panacea Biotec sites will be supplied to the international partners of RDIF. - REUTERS×
New Delhi-based firm likely to announce in two weeks
New Delhi-based Panacea Biotec is likely to announce details about its contract with Russian Direct Investment Fund (RDIF) for the manufacturing of Sputnik V vaccine within 15 days.
Sources told
BusinessLine that the company will start production within 60-90 days of the announcement in its three facilities in India.

Delhi , India , Russia , Lalru , Punjab , Russian , Baddi-himachal-pradesh , Stelis-biopharma , Virchow-biotech-private , Russian-direct-investment-fund , New-delhi-based-panacea-biotec , Panacea-biotec

Transasia opens facility at AMTZ

Transasia opens facility at AMTZ
Updated:
Updated:
COVID test kits to be manufactured
Share Article
COVID test kits to be manufactured
Transasia Bio-Medicals Ltd. on Thursday announced the formal inauguration of its state-of-the-art medical devices manufacturing plant at the Andhra Pradesh MedTech Zone (AMTZ) here.
The largest of its kind facility in Asia spread over 35,000 sft will manufacture ErbaLisa COVID-19 IgG ELISA test kits, RT-PCR kits and rapid test kits for India and other emerging markets.
The new facility was virtually inaugurated by Minister for Industries, Commerce and IT Mekapati Goutham Reddy, Telecommunications Regulatory Authority of India (TRAI) chairperson P.D. Vaghela, Scientific Secretary to Principal Scientific Adviser, Government of India, Arabinda Mitra, Special Chief Secretary to Government (Industries and Commerce) R. Karikal Valven, in the presence of MD and CEO of AMTZ Jitendra Sharma, founder and chairman of Transasia-Erba International Group of Companies Suresh Vazirani and vice-president, R&D Reagents, Transasia Bio-Medicals Ltd. Manoj Chugh.

Mumbai , Maharashtra , India , Mekapati-goutham-reddy , Jitendra-sharma , R-karikal-valven , Transasia-bio , Andhra-pradesh-medtech , Baddi-himachal-pradesh , Manoj-chugh , Arabinda-mitra , Transasia-erba-international-group-of-companies-suresh-vazirani

Panacea Biotec share rises 20% on pact to make 100 million doses of Sputnik V vaccine per year

Story
Panacea Biotec share rises 20% on pact to make 100 million doses of Sputnik V vaccine per year
Share of the pharma firm rose 19.99% to Rs 220.85 against previous close of Rs 184.40 on BSE. The stock opened with a gain of 15.68% at Rs 212.90
BusinessToday.In | April 6, 2021 | Updated 10:40 IST
Panacea Biotec stock is trading higher than 5 day, 20 day, 50 day, 100 day and 200 day moving averages.
Panacea Biotec share rose 20% today after the drug maker said it has inked pact with Russian Direct Investment Fund (RDIF) to produce 100 million doses per year of the Sputnik V COVID-19 vaccine in India. Share of the pharma firm rose 19.99% to Rs 220.85 against previous close of Rs 184.40 on BSE.

Delhi , India , Russia , Lalru , Punjab , Russian , Baddi-himachal-pradesh , Kirill-dmitriev , Rajesh-jain , Russia-gamaleya-national-research-institute-of-epidemiology , Ministry-of-health-russia-on , Russian-direct-investment-fund

COVID-19: Panacea Biotec to produce 100 million doses of Sputnik V in India annually

COVID-19: Panacea Biotec to produce 100 million doses of Sputnik V in India annually
Production of Sputnik V at Panacea Biotec sites will help facilitate global supply of Sputnik V to international partners of RDIF.
BusinessToday.In | April 5, 2021 | Updated 21:34 IST
Panacea Biotec MD Rajesh Jain said the company will produce Sputnik V in its internationally accredited facilities.
Panacea Biotec on Monday said it has entered into an agreement with the Russian Direct Investment Fund (RDIF) to produce 100 million doses of COVID-19 vaccine Sputnik V in India annually.
Production of Sputnik V at Panacea Biotec sites will help facilitate global supply of Sputnik V to international partners of RDIF, the New-Delhi based company said in a release. Panacea Biotec has production facilities at Baddi (Himachal Pradesh), Lalru (Punjab) and Delhi.

Delhi , India , Russia , Lalru , Punjab , Russian , Baddi-himachal-pradesh , Kirill-dmitriev , Rajesh-jain , Stelis-biopharma , Virchow-biotech-private , India-subject-expert-committee